SAB Biotherapeutics, Inc. (SABS)

Market Cap	24.16M
Revenue (ttm)	377,835
Net Income (ttm)	-34.28M
Shares Out	9.29M
EPS (ttm)	-3.70
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	553,867
Open	2.450
Previous Close	2.490
Day's Range	2.430 - 2.850
52-Week Range	1.000 - 6.600
Beta	0.53
Analysts	Strong Buy
Price Target	11.60 (+346.15%)
Earnings Date	Aug 7, 2025

About SABS

SAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of human polyclonal immunotherapeutic antibodies to address immune system disorders. It has applied advanced genetic engineering to develop transchromosomic for hyperimmunization and plasma collection, as well as develops product to treat diseases, including type 1 diabetes (T1D) and other autoimmune disorders. In addition, its lead product candidate SAB-142, a human, multi-target anti-thymocyte globulin treatment, currently under Phase 2b clinical...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2014
• Employees: 63
• Stock Exchange: NASDAQ
• Ticker Symbol: SABS
• Website: https://www.sabbiotherapeutics.com

Financial Performance

In 2024, SAB Biotherapeutics's revenue was $1.32 million, a decrease of -40.94% compared to the previous year's $2.24 million. Losses were -$34.11 million, -19.17% less than in 2023.

Analyst Summary

According to 5 analysts, the average rating for SABS stock is "Strong Buy." The 12-month stock price target is $11.6, which is an increase of 346.15% from the latest price.

Price Target

$11.6

(346.15% upside)

Analyst Consensus: Strong Buy